Benzodiazepine Use and Hepatitis C Seroconversion in a Cohort of Persons Who Inject Drugs.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 26985601.
- Also identified by DOI 10.2105/AJPH.2016.303090 and PMC identifier 4880240.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To examine the relationship between benzodiazepine (BZD) use and HCV seroconversion in 2 linked prospective cohorts of persons who inject drugs (PWID). We examined prospective cohorts of 440 PWID (baseline BZD users: n = 102; 23.2%) from the AIDS Care Cohort to Evaluate Access to Survival Services (ACCESS) and the Vancouver Injection Drug Users Study (VIDUS) cohorts, followed-up from 1996 to 2013 in Vancouver, Canada. At baseline, the prevalence of HCV was higher among those who used BZD (80.5% vs 61.5%; P < .001). After adjustment, BZD use remained independently associated with increased rates of HCV seroconversion (adjusted rate ratio = 1.67; 95% confidence interval = 1.05, 2.66). BZD use is independently associated with HCV seroconversion in a population of PWID.
Medical subject headings
- Benzodiazepines
- Hepacivirus
- Hepatitis C
- Seroconversion
- Substance Abuse, Intravenous